Recent Advances and Perspectives in Cancer Drug Design

Abstract

Cancer is one of the leading causes of death worldwide. With the increase in life expectancy, the number of cancer cases has reached unprecedented levels. In this scenario, the pharmaceutical industry has made significant investments in this therapeutic area. Despite these efforts, cancer drug research remains a remarkably challenging field, and therapeutic innovations have not yet achieved expected clinical results. However, the physiopathology of the disease is now better understood, and the discovery of novel molecular targets has refreshed the expectations of developing improved treatments. Several noteworthy advances have been made, among which the development of targeted therapies is the most significant. Monoclonal antibodies and antibody-small molecule conjugates have emerged as a worthwhile approach to improve drug selectivity and reduce adverse effects, which are the main challenges in cancer drug discovery. This review will examine the current panorama of drug research and development (R&D) with emphasis on some of the major advances brought to clinical trials and to the market in the past five years. Breakthrough discoveries will be highlighted along with the medicinal chemistry strategies used throughout the discovery process. In addition, this review will provide perspectives and updates on the discovery of novel molecular targets as well as drugs with innovative mechanisms of action.

Cytotoxic and Antiproliferative Effects of Preussin, a Hydroxypyrrolidine Derivative from the Marine Sponge-Associated Fungus Aspergillus candidus KUFA 0062, in a Panel of Breast Cancer Cell Lines and Using 2D and 3D Cultures

“…Since cancer incidence keeps rising each year [1,2], the scientific community and pharmaceutical industry have focused their attention on the discovery of new drugs or drug adjuvants to improve the fight against this disease [3]. Consequently, one hotspot of interest for drug discovery is anticancer drugs, whose rising costs have been applied to drug research and development [3,4].…”

Phosphine- and Isatin-Copper Complexes: Anticancer Activity, Mechanisms of Action and Structure-Activity Relationship Examples from the Last Ten Years

“…It is hypothesized that Cu(I) complexes had efficient uptake through lipid cell membrane than Cu(II) derivatives [20]. Therefore, the structure-activity relationship (SAR) analysis disclosed that cytotoxic profile of the Cu(I) compounds is dependent on the lipophilic property of the fluoroquinolone ligand [21].…”

Hexon-based scaffold for generation of diagnostic monoclonal antibodies against diverse adenovirus types

“…Одним из перспективных направлений является получение терапевтических МКА к возбудителям вирусных и бактериальных инфекций. Препараты на основе МКА успешно применяются при лечении некоторых видов рака (рак толстого кишечника, немелкоклеточный рак легких, глиобластома, метастазирующий рак почки) и аутоиммунных заболеваний (ревматоидный артрит, псориаз, болезнь Крона), а также для подавления иммунной системы после трансплантации органов [14].…”